GlassScriptPhysician profile
Ronald N Chaplan
NPI 1255403531
$864.67
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $105 · 2021: $429.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $253.22 | 2019-2021 | |
| Stryker Corporation | $91.93 | 2020 | |
| Depuy Synthes Sales INC. | $82.18 | 2019-2021 | |
| Heron Therapeutics, INC. | $79.94 | 2021 | |
| Evolution Surgical, INC | $72.78 | 2019 | |
| Abbott Laboratories | $69.35 | 2021 | |
| Bioventus LLC | $50.08 | 2019-2021 | |
| Radius Health, INC. | $37.29 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $28.29 | 2019 | |
| Smith+Nephew, INC. | $28.10 | 2021 | |
| Covidien LP | $26.32 | 2019 | |
| Next Science LLC | $24.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.04 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Chaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.